Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. (Q38109282)

From Wikidata
Jump to navigation Jump to search
scientific article published on 22 May 2013
edit
Language Label Description Also known as
English
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
scientific article published on 22 May 2013

    Statements

    Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit